Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Prognostic Factors in Acute Myeloid Leukemia

January 7th 2016

Risk Stratification of Myelodysplastic Syndromes and AML

January 7th 2016

Development of Secondary Acute Myeloid Leukemias

January 7th 2016

Pathobiology of Acute Myeloid Leukemias (AML)

January 7th 2016

Dr. Swords on Anti-Tumor Effects of IMG-98 in AML

January 6th 2016

Ronan T. Swords, MD, discusses preclinical findings demonstrating that the small-molecule inhibitor IMG-98 effectively augments pro-differentiation effects of all-trans-retinoic acidâ€“based therapies in acute myeloid leukemia.

Dr. Rizzo on Impact of Age on Survival Outcomes in MDS After HCT

December 31st 2015

J. Douglas Rizzo, MD, MS, assistant scientific professor, Center for International Blood and Marrow Transplant Research, professor of Medicine, Medical College of Wisconsin, discusses a study that examined if age affects survival outcomes in patients with myelodysplastic syndromes who receive a hematopoietic cell transplant.

Emerging Therapeutic Alternatives in Acute Lymphoblastic Leukemia

December 29th 2015

CAR T-Cell Immunotherapy in Acute Lymphoblastic Leukemia

December 29th 2015

Optimizing Blinatumomab Use in Acute Lymphoblastic Leukemia

December 29th 2015

Adverse Event Profile of Blinatumomab in ALL

December 29th 2015

Using Blinatumomab in Acute Lymphoblastic Leukemia

December 29th 2015

Salvage Therapy in Acute Lymphoblastic Leukemia

December 29th 2015

MRD Monitoring in Acute Lymphoblastic Leukemia

December 29th 2015

Allogeneic Stem Cell Transplant in ALL

December 29th 2015

Minimal Residual Disease in ALL

December 29th 2015

Targeted and Chemotherapy Treatment Options in ALL

December 29th 2015

Induction and Post-Induction Therapy for Adult ALL

December 29th 2015

Acute Lymphoblastic Leukemia Patient Population

December 29th 2015

Overview on Management of Acute Lymphoblastic Leukemia

December 29th 2015

TP53: The Elephant in the Precision Oncology Room

December 26th 2015

One of the central reasons that curing cancer has been so problematic is the dysfunction of TP53, the single most common genetic alteration in cancer.